Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Recruiting2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

recruiting250%
completed250%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_1

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

NCT05079282
recruitingphase_1

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

NCT06547528
completedphase_1

Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685

NCT05332704
completedphase_1

Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male Subjects

NCT04079062

Clinical Trials (4)

Showing 4 of 4 trials
NCT05079282Phase 1

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

Recruiting
NCT06547528Phase 1

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

Recruiting
NCT05332704Phase 1

Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685

Completed
NCT04079062Phase 1

Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male Subjects

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4